anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tri-Sprintec® (norgestimate and ethinyl estradiol tablets USP) 0.18 mg/0.035 mg are gray, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and 985 on the other side; 0.215 mg/0.035 mg are light blue, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and 986 on the other side; 0.25 mg/0.035 mg are blue, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and 987 on the other side; placebo tablets are white, round, flat-faced, beveled-edge, unscored tablets, debossed with stylized b on one side and 143 on the other side.

Tri-Sprintec® (norgestimate and ethinyl estradiol tablets USP) are packaged in cartons of six blister cards. Each card contains 28 tablets as follows: Each gray tablet contains 0.18 mg of the progestational compound, norgestimate, USP, together with 0.035 mg of the estrogenic compound, ethinyl estradiol, USP. Each light blue tablet contains 0.215 mg of the progestational compound, norgestimate, USP, together with 0.035 mg of the estrogenic compound, ethinyl estradiol, USP. Each blue tablet contains 0.25 mg of the progestational compound, norgestimate, USP, together with 0.035 mg of the estrogenic compound, ethinyl estradiol, USP, and the 7 white placebo tablets contain inert ingredients.

NDC: 0555-9108-58

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
Compositions and methods are provided for treating Prostate Cancer (PC) in a subject, comprising administering to the subject a therapeutically effective amount of a polypeptide agent that inhibits EphB4 or ephrin B2-mediated function. More particularly, methods are provided for treating PC that lacks PTEN or that is refractory to treatment using Androgen Receptor (AR) targeted therapy. Importantly, in established pre-castration and post-castration tumors, soluble EphB4 therapeutic agents prevent tumor formation and induce tumor regression. Surprisingly, Androgen Receptor (AR) levels also decreased with treatment. Analysis of PI3K subtype showed that downregulation of PI3K p110 β alone directly regulated AR levels, and therefore the AR decline was rescued by ectopic expression of PI3K β. Thus, EphB4 is a novel target for prostate cancer.
PURPOSE:The titled preparation obtained by dispersing at least one cyclosporin into water containing a surface active agent. CONSTITUTION:At least one cyclosporin (e.g., cyclosporin A, cyclosporin B, cyclosporin C, etc.) is dispersed into water containing a surface active agent (e.g., glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, etc.), to give a cyclosporin-containing drug capable of keeping a high concentration of cyclosporin in lymphocytic tissue. The drug may contain a middle - higher fatty acid (e.g., myristic acid, stearic acid, etc.) besides the essential component. In the blending ratio of the essential components, in the case of cyclosporin A, the drug comprises 1pt.wt. cyclosporin A, 1-50pts.wt., preferably 10-30pts.wt. surface active agent, and 100-1,000pts.wt., preferably 200-500pts. wt. water.
Participants will receive 1x Salivary TTMV-HPV DNA Test. If test is negative there will not be follow up, if test is positive participants will have repeat Salivary TTMV-HPV DNA Test, a blood test and head and neck exam.
OBJECTIVE: Status epilepticus (SE) is the second most common neurological emergency in adults. Despite improvements in the management of acute neurological conditions over the last decade, mortality is still durably high. Because a gap has emerged between SE management based on clinical practice guidelines (CPGs) and actual clinical practice, we conducted a systematic review of CPGs, assessing their quality, outlining commonalities and discrepancies in recommendations, and highlighting research gaps.
METHODS: We searched the PubMed and EMBASE databases and other gray literature sources (nine among guideline registries, evidence-based medicine databases, point-of-care tools; seven websites of governmental organizations and international neurologic societies) in December 2021 (updated in November 2023). The units of analysis were CPGs that included recommendations on the diagnostic and/or therapeutic management of SE in adults. The quality of the CPGs was assessed using the AGREE II tool.
RESULTS: Fifteen CPGs were included. The "Applicability" domain was assigned the lowest median score of 10%. The domains "Stakeholder Involvement", "Rigor of Development," and "Editorial Independence" were as well generally underrated. Recommendations on general and diagnostic management and on organizational interventions were fragmented and scattered. Recommendations on pre-hospital and hospital treatment of early-onset and refractory SE were broadly agreed, whereas there was less agreement on the treatment model and medications for established SE and super-refractory SE.
SIGNIFICANCE: The CPGs for the management of SE developed in recent years are flawed by several methodological issues and discrepancies in the coverage of important topics. The gap between CPG-based management of SE and actual clinical practice may be due in part to the inherent limitations of the CPGs produced so far.
Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients undergoing coronary stenting. Although in this setting the potent oral P2Y12 inhibitor prasugrel is commonly utilized, there is very limited data on the optimal approach for switching between these therapies. In particular, ruling out a drug-drug interaction (DDI) is critical to this extent as the presence of a DDI would translate into reduced or abolished antiplatelet effects exposing these acute patients to an increased thrombotic risk. There is an unmet need to better elucidate pharmacodynamic profiles associated with the transition from cangrelor to prasugrel therapy. Of note, prasugrel has recently gone off patent and the availability of a generic formulation will favorably impact its use. Pharmacodynamic studies provide some support on the safety of administering prasugrel at the start of cangrelor infusion. However, the available data does not allow to rule out a DDI given that there was no comparator arm in which prasugrel was either given alone or at the end of cangrelor infusion. The methodological approach for this assessment should rely on comprehensive pharmacodynamics investigations aimed to assess levels of P2Y12 receptor inhibition, pharmacokinetic investigations to assess systemic levels of the drug/drug metabolite, and mechanistic investigations by assessment of levels of P2Y12 receptor gene expression. The overarching aim of this investigation is to rule out a DDI when cangrelor and prasugrel are concomitantly administered in patients undergoing coronary stenting.
Later timing of eating has been associated with higher adiposity among adults and children in several studies, but not all. Moreover, studies in younger children are scarce. Hence, this study investigated the associations of the timing of evening eating with BMI Z-score and waist-to-height ratio (WHtR), and whether these associations were moderated by chronotype among 627 preschoolers (3-6-year-olds) from the cross-sectional DAGIS survey in Finland. Food intake was measured with 3-d food records, and sleep was measured with hip-worn actigraphy. Three variables were formed to describe the timing of evening eating: (1) clock time of the last eating occasion (EO); (2) time between the last EO and sleep onset; and (3) percentage of total daily energy intake (%TDEI) consumed 2 h before sleep onset or later. Chronotype was assessed as a sleep debt-corrected midpoint of sleep on the weekend (actigraphy data). The data were analysed with adjusted linear mixed effects models. After adjusting for several confounders, the last EO occurring closer to sleep onset (estimate = -0·006, 95 % CI (-0·010, -0·001)) and higher %TDEI consumed before sleep onset (estimate = 0·0004, 95 % CI (0·00003, 0·0007)) were associated with higher WHtR. No associations with BMI Z-score were found after adjustments. Clock time of the last EO was not significantly associated with the outcomes, and no interactions with chronotype emerged. The results highlight the importance of studying the timing of eating relative to sleep timing instead of only as clock time.
The present invention relates to an integrated transcranial direct current stimulation (tDCS) device and near infrared spectroscopy (fNRS) device-based wearable and portable brain function activation promoting and monitoring system. The integrated tDCS device and fNRS device-based wearable and portable brain function activation promoting and monitoring system comprises: an apparatus in which a tDCS device and a fNRS are integrated; and software remotely controlling the apparatus in which the tDCS device and the fNRS are integrated and managing the measured data. The integrated tDCS device and fNRS device-based wearable and portable brain function activation promoting and monitoring system can measure a hemodynamic activation rate which is brain function activation of a prefrontal cortex in the cerebrum of a user through the wireless tDCS and fNRS device which is small and light. The integrated tDCS device and fNRS device-based wearable and portable brain function activation promoting and monitoring system can extract a high-quality hemodynamic signal of low noise by removing noise generated by an action of a human body and unrelated to brain activation through an additional auxiliary channel. Moreover, the integrated tDCS device and fNRS device-based wearable and portable brain function activation promoting and monitoring system can select and use various current stimulation programs that can improve activation of cognitive ability and concentration and solve depression, stress, and the like. Furthermore, the integrated tDCS device and fNRS device-based wearable and portable brain function activation promoting and monitoring system manages hemodynamic activation information, which is a brain function activation criterion, by being connected to various Bluetooth support devices, such as a smartphone and a laptop while representing low-power consumption of high speed through a low-power Bluetooth module including a Bluetooth communication standard. Moreover, the integrated tDCS device and fNRS device-based wearable and portable brain function activation promoting and monitoring system enables mass production in a short time at low manufacturing costs. The integrated tDCS device and fNRS device-based wearable and portable brain function activation promoting and monitoring system stores the hemodynamic activation information, which is the brain function activation criterion, on a cloud storage and manages the hemodynamic activation information as the form of big data. Furthermore, the integrated tDCS device and fNRS device-based wearable and portable brain function activation promoting and monitoring system can provide an analysis result of hemodynamic activation and a cognition activity game of a difficulty level optimized for an individual based on the hemodynamic activation information.
Scaffold peptides and methods of making and using same. The scaffold peptides have a general structure from the N-terminus to the C-terminus, AH1-linker-AH2. AH1 and AH2 each comprise an alpha helical structure and may fold against each other about the linker to form a bi-helical structure. The scaffold peptide includes alternating polar and non-polar regions. The non-polar regions of the scaffold peptide interact with the hydrophobic regions of the proteins to solubilize same in aqueous solutions without the presence of detergent. In some embodiments, the scaffold peptides are used for hydrophobic protein purification, isolation and/or stabilization.
BACKGROUND: Esophagogastric junction cancer (EJC) refers to malignant tumors that develop at the junction between the stomach and the esophagus. TUSC1 is a recently identified tumor suppressor gene known for its involvement in various types of cancer. The objective of this investigation was to elucidate the regulatory influence of DNA methylation on TUSC1 expression and its role in the progression of EJC.
METHODS: Bioinformatics software was utilized to analyze the expression of TUSC1, enriched pathways, and highly methylated sites in the promoter region. TUSC1 expression in EJC was assessed using quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot (WB), and immunohistochemistry. Methylation-specific PCR was employed to detect the methylation level of TUSC1. To analyze the effects of TUSC1 and 5-AZA-2 on tumor cell proliferation, migration, invasion, cell cycle, and apoptosis, several assays including CCK-8, colony formation, transwell, and flow cytometry were conducted. The expression of MDM2 was assessed using qRT-PCR and WB. WB detected the expression of p53, and p-p53, markers for EJC cell proliferation, epithelial-mesenchymal transition, and apoptosis. The role of TUSC1 in tumor occurrence in vivo was examined using a xenograft mouse model.
RESULTS: TUSC1 expression was significantly downregulated in EJC. Overexpression of TUSC1 and treatment with 5-AZA-2 inhibited the malignant progression of EJC cells. In EJC, low methylation levels promoted the expression of TUSC1. Upregulation of TUSC1 suppressed the expression of MDM2 and activated the p53 signaling pathway. Inactivation of this pathway attenuated the inhibitory effect of TUSC1 overexpression on EJC cell proliferation, migration, invasion, and other behaviors. Animal experiments demonstrated that TUSC1 overexpression inhibited EJC tumor growth and metastasis in vivo.
CONCLUSION: TUSC1 was commonly downregulated in EJC and regulated by methylation. It repressed the malignant progression of EJC tumors by mediating the p53 pathway, suggesting its potential as a diagnostic and therapeutic target for EJC.
Obesity is often associated with sex-dependent metabolic complications, in which altered intestinal barrier function and gut microbiota contribute. We aimed to characterize in mice the sex-dependent effects of a high fat diet on these parameters. Male and female C57BL/6 mice received a standard (SD) or high fat diet (HFD; 60% kcal from fat) during 14 weeks (W14). Body composition, glucose tolerance, insulin sensitivity, intestinal permeability, colonic expression of 44 genes encoding factors involved in inflammatory response and gut barrier function, cecal microbiota, plasma adipokines and white adipose tissue response have been assessed. Both male and female HFD mice exhibited an increase of body weight and fat mass gain and glucose intolerance compared to SD mice. However, only male HFD mice tended to develop insulin resistance associated to increased Tnfα and Ccl2 mRNA expression in perigonadal adipose tissue. By contrast, only female HFD mice showed significant intestinal hyperpermeability that was associated with more markedly altered colonic inflammatory response. Cecal microbiota richness was markedly reduced in both sexes (Observed species) with sex-dependent modifications at the phyla or family level, e.g. decreased relative abundance of Bacillota and Lachnospiraceae in females, increased of Bacteroidaceae in males. Interestingly, some of these microbiota alterations were correlated with peripheral metabolic and inflammatory markers. In conclusions, male and female mice exhibit different responses to a high fat diet with specific changes of gut microbiota, intestinal barrier function, colonic and white adipose tissue inflammation, metabolic markers and body weight gain. The underlying mechanisms should be deciphered in further investigations.
<P>PROBLEM TO BE SOLVED: To improve operation efficiency related with the creating operation of a medical report.  <P>SOLUTION: This report creation support system includes an order table for registering an order in which the content of the creation request of a report is recorded. When a work list is displayed on a display, the list of the order in the order table is displayed. When the order being the object of processing is selected in the work list, and there is an order relevant to the selected order, a guide screen 61 is displayed. On the guide screen 61, a message for notifying a user that the order relevant to the selected order exists and a message for notifying the user that the individual processing of each order or the integrated processing of each order should be selected are displayed.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A body spray assembly includes a container 12 which has an upright position and that is at least partly transparent. A liquid composition in the container is sprayed from the container with a manual spray pump 28. The composition has an oil phase, an aqueous phase and pigment in the form of particles which are effective to form the oil phase into stable droplets 32 that remain in a droplet layer in the aqueous phase 14 after the composition is allowed to stand for a period of time. The droplets are at least partly visible in the container. The spray pump is free of any plastic parts that extend into the droplet layer when the container is in its upright position to avoid rupturing the stable droplets by contact with these parts. The oil phase contains substantially pure fragrance which is free of solubilizer so that the formation of pearls can occur in the container and does not cloud the aqueous phase.
This is a prospective, comparative study of 60 patients diagnosed with grade 2 cataracts (according to LOCS III) that underwent one of the following surgical procedures: Insertion of an extended depth of focus intraocular lens with digital assistance and insertion of an extended depth of focus intraocular lens without digital assistance.

In these patients, a comparison of postoperative visual acuity curves of both groups will be conducted. Visual acuity curves will be designed using the validated digital optotype Democritus Digital Acuity \& Reading Test (DDART). Assessment of visual acuity will be performed at 9 different distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm). Overall visual acuity curves and the area under the curve will be formed through the application as the primary means of evaluating visual capacity. Additionally, the degree of subjective satisfaction of the patient will be evaluated through an interview (NEI-VFQ 25). All examinations will be conducted according to standard clinical practice.
Azithromycin 250 mg tablets are supplied as pink modified capsular shaped, engraved, film-coated tablets containing azithromycin dihydrate equivalent to 250 mg of azithromycin. Azithromycin 250 mg tablets are engraved with "G" on one side and "3060" on the other. These are packaged in bottles and blister cards of 6 tablets.

Azithromycin 500 mg tablets are supplied as pink modified capsular shaped, engraved, film-coated tablets containing azithromycin dihydrate equivalent to 500 mg of azithromycin. Azithromycin 500 mg tablets are engraved with "G" on one side and "3070" on the other. These are packaged in bottles and blister cards of 3 tablets.

Azithromycin for oral suspension after constitution contains a flavored suspension. Azithromycin for oral suspension is supplied to provide 100 mg/5 mL or 200 mg/5 mL suspension in bottles.
The group of school-aged children from Haiti who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
Regimen consists of 2 cycles of high-dose therapy, each followed by stem cell infusion. Cycle 1 consists of high-dose melphalan followed by infusion of approximately 1.5 million cluster of differentiation 34 positive (CD34+) cells. Cycle 2 consists of either TBI-based or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-based high-dose therapy followed by infusion of at least 2 million CD34+ cells.
In may 2014, after Heart or Lung transplantation or assist device implantation, the investigators decided to off-label administered Romiplostim in patients with thrombocytopenia below 100 Giga per liter. The purpose was to reduce platelets transfusion side effects. Romiplostim was used off treatment algorithm was based on previously published data in idiopathic, thrombocytopenia, cirrhotic and hematological patients. The first subcutaneous injection of 1.5 to 2 μg/kg of romiplostim was administered in the postoperative periods. An algorithm based on patient weight and platelet count evolution was established to determine romiplostim doses to administered weekly. Romiplostim posology was adjusted between 2 and 5μg/kg according to platelet count with a maximum of 4 administrations in the ICU. If platelets remained below 50 Giga per liter after 2 injections, bone marrow analysis after hematologist referral was discussed. Platelet count until day 15 after the last injection was monitored to detect thrombocytosis.

In January 2016, the investigators decided to retrospectively assess Romiplostim implementation in the standard of care in the ICU through a Healthcare quality improvement project in a before/after design.
The invention relates to the medicine for external application, specifically speaking, the invention adopts the pure natural bamboo, raw rhubarb and calyx canthus as the main materials, which is the pure natural foot-itching curer having the effects of bigoted bacteria killing, detumescence, acesodyne and itching removing. The invention takes the pure natural perennial woody plant and herb, bamboo, raw rhubarb and calyx canthus as the main materials, and the assistant materials are radix aconiti kusnezoffii and belvedere fruit. The pure natural foot-itching curer is made by decontamination, defect removing and water cleaning of the formulation materials, air-drying, smoldering the smashed bamboo in the container for extracting the bamboo vinegar, water decoction of mixed drugs and mixed package of liquid. The invention has no side effect to the skin and has effects of bigoted bacteria killing, detumescence, acesodyne, apocenosis, detoxification and itching removing. The foot itching can be obviously eliminated by external application for one time, and the foot itching can be cured with no recurrence after five to six times of continuous using, so the invention has the special curative effect to people who suffer the beriberi or the impetigo. The invention is the pure natural foot-itching curer with a unique and scientific composing prescription, coat-effective and easy-to-obtain main materials, convenient preparation and low cost.
OBJECTIVES: I. Determine the feasibility of high-dose cyclophosphamide and filgrastim (G-CSF) in patients with stage IV, relapsed, or progressive low-grade follicular non-Hodgkin's lymphoma. II. Determine the toxic effects of this regimen in these patients, including those with marrow involvement. III. Determine the rates of complete remission (CR) and partial remission and time to failure in previously treated and untreated patients. IV. Determine the effectiveness of this regimen in eradicating bcl-2 rearrangements, as determined by polymerase chain reaction (PCR), in previously untreated patients. V. Correlate the duration of CR to PCR results in responding patients.

OUTLINE: Patients are stratified according to prior treatment (yes vs no). Patients receive cyclophosphamide IV over 90 minutes on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 3 and continuing until blood counts recover. Treatment continues every 2 weeks for 4 courses in the absence of disease progression or stable disease. Patients who achieve complete remission (CR) after completion of course 4 receive 2 additional courses. Patients who achieve partial remission (PR) after completion of course 4 receive 2 additional courses, and those who achieve CR after completion of course 6 receive 2 additional courses. Patients are followed every 2 months for 6 months, every 6 months for 2 years, and then annually thereafter.